Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
72
天
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data
作者
Ming-Yu Lai; Hao-Xiang Wu; Ming-Ming He; Wen-Long Guan; Sheng Xu; Han Hu; Ya-Ling Xu; Feng-Hua Wang; Rui-Hua Xu; Miao-Zhen Qiu展开收起
作者单位
1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China; 2. Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China; 3. Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China; 4. Global Statistics and Data Science, BeOne Medicines, Ltd., Shanghai, China; 5. Clinical Biomarker Sciences and CDx Development, BeOne Medicines, Ltd., Beijing, China; 6. Clinical Development, BeOne Medicines, Ltd., Shanghai, China展开收起
101
天
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment
作者
Monika Szczepanowski; Johanna Richter; Sonja Bendig; Lorenz Bastian; Miriam Kelm; Veronika Beck; Thomas Beder; Guranda Chitadze; Michaela Kotrová; Johannes Duell; Christoph Faul; Johannes Gärtner; Alina Hartmann; Britta Kehden; Eva Maria Murga Penas; Martin Neumann; Matthias Ritgen; Wiebke Schrader; Björn Steffen; Heiko Trautmann; Andreas Viardot; Thomas Burmeister; Claudia D. Baldus; Stefan Schwartz; Nicola Gökbuget; Monika Brüggemann展开收起
作者单位
1. Medicine Department II, Hematology and Oncology, University Medical Center Schleswig-Holstein (UKSH), Kiel, Germany; 2. University Cancer Center Schleswig-Holstein (UCCSH), Kiel, Germany; 3. Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4. Clinical Research Unit ’CATCH ALL’ (KFO 5010), Kiel, Germany; 5. Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany; 6. Internal Medicine II, University Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen, Tübingen, Germany; 7. Department of Medicine 5, Oncology, Hematology and Bone Marrow Transplantation Unit, Klinikum Nürnberg Nord, Nürnberg, Germany; 8. Institute of Human Genetics, University Medical Center Schleswig- Holstein (UKSH), Lübeck, Germany; 9. Medicine Department II, Johann Wolfgang Goethe University, Frankfurt, Germany; 10. Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany; 11. Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Campus Virchow Klinikum, Charité - Universitätsmedizin, Berlin, Germany; 12. Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin , Berlin, Germany; 13. Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany; 14. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 15. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany展开收起
58
天
Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting
作者
Yan-Ruide Li; Zhengyao Shao; Haochen Nan展开收起
作者单位
1. Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, USA; 2. Department of Bioengineering, University of California, Los Angeles, USA; 3. Goodman-Luskin Microbiome Center, University of California, Los Angeles, USA; 4. Department of Pharmacology, University of California San Diego, La Jolla, USA展开收起
66
天
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer
作者
Chang Liu; Hongxi Zeng; Jiarui Li; Panpan Zhang; Dan Liu; Miao Zhang; Ran Xue; Jifang Gong; Xiaotian Zhang; Yu Sun; Lin Shen; Changsong Qi展开收起
作者单位
1. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China; 2. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; 3. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; 4. State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China; 5. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China展开收起
71
天
Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density
作者
Haochen Nan; Xinyuan Shen; Youcheng Yang; Shubing Wang; Yan-Ruide Li展开收起
作者单位
1. Department of Bioengineering, University of California, Los Angeles, USA; 2. Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, USA; 3. Goodman-Luskin Microbiome Center, University of California, Los Angeles, USA展开收起
126
天
BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88 L265P -induced PIM1 stability
作者
Yan Yuan; Bo Dai; Haoshu Zhong; Jiajun Zheng; Zhen Fan; Di Chen; Qian Wang; Hao Wu; Yuan Li; Ping Zhu; Tianling Ding; Shu Wang; Kunpeng Wu; Yu Zhang; Zhenhua Wang; Rui Feng; Fengping Zhu; Kang Zheng; Zhiyong Qin; Bojie Yang; Hong Chen; Xiaolei Lin; Yu Yao; Dongxiao Zhuang; Zhifeng Shi; Ying Mao; Tong Chen展开收起
作者单位
1. Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China; 2. Center of Precision Medicine for Blood Diseases, Fudan University, Shanghai, China; 3. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China; 4. Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China; 5. Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China; 6. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China; 7. Institute of Medicine, Huashan Hospital, Fudan University, Shanghai, China; 8. School of Data Science, Fudan University, Shanghai, China展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天